Terms: = Ovarian cancer AND CEP17
4 results:
1. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
[TBL] [Abstract] [Full Text] [Related]
2. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
Schlüter B; Gerhards R; Strumberg D; Voigtmann R
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
[TBL] [Abstract] [Full Text] [Related]
3. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
Farley J; Fuchiuji S; Darcy KM; Tian C; Hoskins WJ; McGuire WP; Hanjani P; Warshal D; Greer BE; Belinson J; Birrer MJ
Gynecol Oncol; 2009 Jun; 113(3):341-7. PubMed ID: 19272639
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.
Troxell ML; Bangs CD; Lawce HJ; Galperin IB; Baiyee D; West RB; Olson SB; Cherry AM
Am J Clin Pathol; 2006 Nov; 126(5):709-16. PubMed ID: 17050068
[TBL] [Abstract] [Full Text] [Related]
